Twenty-six million Americans take aspirin and there are 13 million Plavix prescriptions written annually to prevent platelets from initiating aggregation (clumping) that leads to recurrent heart attacks, strokes, blood clotting and stent occlusions. Studies show that over 20% of these individuals are resistant to these therapies leaving them unprotected and at higher risk for cardiovascular complications. Therefore, it is important for patients taking aspirin or Plavix to monitor their anti-platelet therapy on an ongoing basis.

For years, cardiovascular patients have been taking anti-platelet medications to prevent life-threatening adverse cardiovascular events such as heart attacks, strokes and stent occlusions—without knowing whether their therapies were effective. There is now a simple, inexpensive solution to help physicians and their patients monitor and assess anti-platelet therapies.—ThromboVision’s groundbreaking ThromboGuide platelet therapy monitoring system.

The ThromboGuide Platelet Function Analyzer (T-Guide) measures platelet aggregation using a patented light scattering technology developed by scientists at Brigham Young University and Thrombodyne, Inc. The T-Guide methodology identifies and monitors the function of platelets and how they are affected by anti-platelet drugs such as aspirin (ASA) and clopidogrel (Plavix®).

Thrombovision will provide cost effective, easy to use diagnostic tools and information for healthcare practitioners. Thrombovision offers efficient and accurate diagnostic testing for anti-platelet therapy which provides physicians with the necessary data to individualize patient care around cardiovascular risk assessment and modification at the point of service. Healthcare providers can use the CLIA waived ThromboGuide system to initiate and monitor patient therapy.  By providing effective cardiovascular risk assessment and modification solutions, Thrombovision’s goal is to be a leading contributor of diagnostic tools and information for immediate risk assessment and modification of cardiovascular disease and anti-platelet function.